The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion
Paying $1.5bn Upfront To Buy Chemoproteomics Specialist
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
